- Home
- SCLX vs IAE Comparison
SCLX vs IAE Comparison
Compare SCLX & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- IAE
- Stock Information
- Founded
- SCLX 2011
- IAE 2007
- Country
- SCLX United States
- IAE United States
- Employees
- SCLX N/A
- IAE N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- IAE Trusts Except Educational Religious and Charitable
- Sector
- SCLX Health Care
- IAE Finance
- Exchange
- SCLX Nasdaq
- IAE Nasdaq
- Market Cap
- SCLX 72.5M
- IAE 68.1M
- IPO Year
- SCLX N/A
- IAE N/A
- Fundamental
- Price
- SCLX $0.45
- IAE $6.11
- Analyst Decision
- SCLX Strong Buy
- IAE
- Analyst Count
- SCLX 3
- IAE 0
- Target Price
- SCLX $11.33
- IAE N/A
- AVG Volume (30 Days)
- SCLX 184.3K
- IAE 46.3K
- Earning Date
- SCLX 03-11-2025
- IAE 01-01-0001
- Dividend Yield
- SCLX N/A
- IAE 10.21%
- EPS Growth
- SCLX N/A
- IAE N/A
- EPS
- SCLX N/A
- IAE N/A
- Revenue
- SCLX $55,152,000.00
- IAE N/A
- Revenue This Year
- SCLX $32.77
- IAE N/A
- Revenue Next Year
- SCLX $50.71
- IAE N/A
- P/E Ratio
- SCLX N/A
- IAE N/A
- Revenue Growth
- SCLX 9.41
- IAE N/A
- 52 Week Low
- SCLX $0.38
- IAE $5.31
- 52 Week High
- SCLX $2.63
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- SCLX 42.08
- IAE 49.07
- Support Level
- SCLX $0.40
- IAE $5.94
- Resistance Level
- SCLX $0.53
- IAE $6.13
- Average True Range (ATR)
- SCLX 0.05
- IAE 0.07
- MACD
- SCLX 0.01
- IAE 0.01
- Stochastic Oscillator
- SCLX 47.59
- IAE 62.96
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.